French pharmaceutical giant Sanofi entered into a strategic licensing agreement with California-based Kali Therapeutics to secure exclusive worldwide rights to KT501. This trispecific antibody represents a next-generation approach to treating autoimmune diseases.
Key deal components and technological breakthroughs:
-
Financial Terms: Sanofi will provide $180 million in near-term payments, with potential development and commercial milestones reaching up to $1.05 billion. Kali is also eligible for tiered royalties on future net sales.
-
Multi-Target Mechanism: KT501 simultaneously binds to three antigens on B cells (CD3, CD19, and BCMA). It utilizes a unique “masking technology” designed to decouple potency from toxicity, aiming to prevent the off-target side effects and cytokine release syndromes often associated with T-cell engagers.
-
Clinical Progress: Earlier this month, dosing began for the first-in-human Phase 1a trial involving adult subjects with rheumatoid arthritis. Results regarding safety, tolerability, and pharmacokinetics are anticipated in 2027.
-
Sanofi’s Strategic Vision: This deal continues Sanofi’s aggressive expansion into the Immunology and Inflammation (I&I) sector as it prepares for the loss of exclusivity of its blockbuster Dupixent in the early 2030s. This follows recent alliances with Sino Biopharmaceutical and AI-driven Earendil Labs.
The collaboration highlights the potential of state-of-the-art protein engineering to provide safer and more effective therapeutic options for patients worldwide.
Source: https://pharmaphorum.com/news/sanofi-pays-180m-rights-kali-autoimmune-drug